Conversations with Oncology Investigators Bridging the Gap between Research and Patient Care


LymphomaCLLUpdate117

Interview with Stephen Maxted Ansell, MD, PhD

Track 1: Biologic rationale for the high levels of activity of anti-PD-1/PD-L1 checkpoint inhibitors in Hodgkin lymphoma (HL)
Track 2: Case discussion: A 26-year-old man with relapsed/refractory HL achieves a prolonged response with a checkpoint inhibitor
Track 3: Durable objective responses to anti-PD-1 agents for advanced HL
Track 4: Tolerability of immune checkpoint inhibitors for advanced HL
Track 5: Phase II trial of brentuximab vedotin with nivolumab for patients with untreated HL who are older than age 60 or unable to receive doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD)
Track 6: Five-year survival with brentuximab vedotin for relapsed/refractory HL
Track 7: Case discussion: A 47-year-old woman with relapsed/refractory follicular lymphoma (FL) achieves a durable partial response to idelalisib
Track 8: Immune-related toxicities of FDA-approved (idelalisib) and investigational (copanlisib) PI3K inhibitors for indolent non-Hodgkin lymphoma (NHL)
Track 9: Rituximab alone or in combination with chemotherapy for patients with FL
Track 10: Primary results of the Phase III GALLIUM study: Obinutuzumab-based induction and maintenance therapy prolongs progression-free survival (PFS) for patients with previously untreated FL
Track 11: Investigation of anti-PD-1/PD-L1 antibodies for NHL
Track 12: Case discussion: A 55-year-old man with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receives chimeric antigen receptor T-cell (CAR-T) therapy
Track 13: Clinical experience with CAR-T therapy-associated toxicities
Track 14: Case discussion: A 61-year-old woman with relapsed/refractory peripheral T-cell lymphoma (PTCL) receives brentuximab vedotin
Track 15: Relationship between CD30 expression and response to brentuximab vedotin in patients with lymphomas
Track 16: Sequencing romidepsin, pralatrexate and belinostat for PTCL
Track 17: Recent advances in the management of mantle cell lymphoma
Track 18: Clinical experience with ibrutinib for Waldenström macroglobulinemia

Interview with Ann S LaCasce, MD, MMSc

Track 1: Clinical and investigational strategies with brentuximab vedotin for advanced-stage HL
Track 2: Ongoing investigation of checkpoint inhibitors and/or brentuximab vedotin in earlier lines of therapy for HL
Track 3: Case discussion: A 49-year-old man with unmutated chronic lymphocytic leukemia (CLL) initially treated with FCR (fludarabine/cyclophosphamide/rituximab) experiences disease progression and receives ibrutinib/obinutuzumab on a clinical trial
Track 4: Activity and tolerability of ibrutinib/obinutuzumab
Track 5: Similarities and differences between the Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib for CLL
Track 6: Case discussion: An 87-year-old man with previously treated trisomy 12-positive, non-del(17p) CLL and demonstrated intolerance to ibrutinib receives venetoclax
Track 7: Investigating the potential role of a finite duration of ibrutinib treatment
Track 8: Perspective on the current roles of idelalisib and CAR-T therapy in CLL
Track 9: Case discussion: A 71-year-old woman with transformed FL achieves a near complete response to single-agent lenalidomide before allogeneic stem cell transplant
Track 10: Improvement in PFS with the addition of maintenance lenalidomide compared to observation for patients with relapsed DLBCL not eligible for autologous stem cell transplant
Track 11: Viewpoint on the use of maintenance therapy with an anti-CD20 antibody for indolent and aggressive lymphomas
Track 12: Therapeutic options for patients with “double-hit” lymphomas
Track 13: Activity of nivolumab for relapsed/refractory primary central nervous system lymphoma
Track 14: Case discussion: A 66-year-old man with mantle cell lymphoma undergoes autologous stem cell transplant followed by maintenance rituximab
Track 15: Case discussion: A 58-year-old man with relapsed/refractory DLBCL receives CD19 CAR-T therapy
Track 16: Second opinion: Therapeutic approach for a 66-year-old patient with HL treated with ABVD who develops bleomycin-related pneumocystis pneumonia
 
FACULTY:
 
Stephen Maxted Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota
 
Ann S LaCasce, MD, MMSc
Program Director
Fellowship in Hematology/Oncology
Associate Professor of Medicine
Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida